Elagolix: First Global Approval
- 186 Downloads
Elagolix (ORILISSA™), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women. In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain associated with endometriosis. This approval was based on positive results in two replicate phase III trials; additional phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication. Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clinical development for heavy menstrual bleeding associated with uterine fibroids in the aforementioned locations. This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain associated with endometriosis.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.AbbVie Inc. Prescribing information for OrilissaTM (elagolix) tablets, for oral use. 2018. http://www.accessdata.fda.gov/. Accessed 15 Aug 2018.
- 4.AbbVie. AbbVie receives US FDA approval of ORILISSA™ (elagolix) for the management of moderate to severe pain associated with endometriosis. 2018. https://news.abbvie.com/. Accessed 15 Aug 2018.
- 5.Abbott. Abbott and Neurocrine announce global agreement to develop and commercialize elagolix for the treatment of endometriosis [media release] 16 Jun 2010. http://www.abbott.com
- 6.Neurocrine Biosciences Inc. Neurocrine biosciences reports third quarter 2010 results [media release] 28 Oct 2010. http://www.neurocrine.com
- 7.Neurocrine Biosciences Inc. Form 10-K. 2015. https://www.sec.gov/. Accessed 7 Aug 2018.
- 9.Ng J, Salem A, Carter D, et al. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females. Clin Pharmacol Ther. 2016;99(Suppl 1):S54–5.Google Scholar
- 10.Ng J, Salem A, Carter D, et al. Effect of the coadministration of ketoconazole on the pharmacokinetics and safety of elagolix in healthy premenopausal females. Clin Pharmacol Ther. 2016;99(Suppl 1):S55.Google Scholar
- 13.Acs N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord. 2015;7(2):56–62.Google Scholar
- 17.AbbVie, Neurocrine Biosciences Inc. AbbVie announces positive topline results from phase 3 study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 21 Feb 2018.
- 18.AbbVie. AbbVie announces positive topline results from second phase 3 study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 13 Mar 2018.
- 19.AbbVie. AbbVie announces positive topline results from phase 3 extension study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 22 Aug 2018.
- 20.Stewart E, Owens C, Duan WR, et al. Elagolix alone and with add-back decreases heavy menstrual bleeding in women with uterine fibroids. Conference Abstract. 2017.Google Scholar